AbbVie Inc.
Explore AbbVie
Core profile pages, annual revenue records, and related research hubs for this company.
AbbVie Inc.
Explore AbbVie
Core profile pages, annual revenue records, and related research hubs for this company.
Business Model Analysis
Annual Revenue: $61.2B (FY2025)
AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.
AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.
AbbVie earns revenue from prescription medicines and aesthetics products sold through healthcare systems, insurers, specialists, distributors, and aesthetic practices.
Immunology is AbbVie's largest segment, with FY2025 global net revenue of $30.406 billion.
Skyrizi and Rinvoq are AbbVie's main post-Humira growth drugs, together generating $25.866 billion in FY2025 net revenue.
Botox gives AbbVie both therapeutic revenue and cash-pay aesthetics exposure through the Allergan Aesthetics portfolio.
AbbVie uses acquisitions to add late-stage or commercial assets, but most revenue still comes from internally managed global medicine franchises.